Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Sanofi SA — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.63 (market cap $7.77B), while Sanofi SA trades at $40.19 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 12.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Sanofi SA pays a 6.01% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Sanofi SA for 94 Days on average.
| PDBC | SNY | |
|---|---|---|
Market Cap | $7.77B | $95.18B |
Volume | 6,100,303 | 2,995,646 |
52-Week High | $20.10 | $52.34 |
52-Week Low | $13.16 | $39.51 |
Typical Hold Time | 56 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.41 with a slight 0.26% decline. Technical indicators show a neutral overall signal with bullish moving averages. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodities amid geopolitical tensions. Recent institutional activity shows mixed signals with significant short interest growth alongside new institutional investments.
The outlook for PDBC remains tied to commodity market dynamics, with potential upside from continued geopolitical tensions and defensive portfolio shifts. However, risks include the 215% surge in short interest and commodity price volatility. The ETF offers exposure to broad commodities diversification but faces headwinds from potential market normalization.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
